Regenxbio Inc (RGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regenxbio Inc (RGNX) has a cash flow conversion efficiency ratio of -3.614x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-76.19 Million) by net assets ($21.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Regenxbio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Regenxbio Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Regenxbio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Regenxbio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regenxbio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BLD Plantation Bhd
KLSE:5069
|
0.136x |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
0.039x |
|
Sidus Space Inc
NASDAQ:SIDU
|
-0.119x |
|
RiverNorth Flexible Municipal Income Fund II Inc
NYSE:RFMZ
|
N/A |
|
Suzhou Shijing Environmental Technology Co.Ltd.
SHE:301030
|
N/A |
|
Patel Engineering Limited
NSE:PATELENG
|
0.097x |
|
Ercros
MC:ECR
|
0.130x |
|
Southern Score Builders Berhad
KLSE:0045
|
0.004x |
Annual Cash Flow Conversion Efficiency for Regenxbio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Regenxbio Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Regenxbio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $102.73 Million | $-123.96 Million | -1.207x | -80.97% |
| 2024-12-31 | $259.65 Million | $-173.12 Million | -0.667x | +4.83% |
| 2023-12-31 | $311.74 Million | $-218.41 Million | -0.701x | -74.30% |
| 2022-12-31 | $516.20 Million | $-207.49 Million | -0.402x | -240.36% |
| 2021-12-31 | $764.30 Million | $218.88 Million | 0.286x | +300.10% |
| 2020-12-31 | $377.75 Million | $-54.06 Million | -0.143x | +40.18% |
| 2019-12-31 | $450.20 Million | $-107.70 Million | -0.239x | -216.33% |
| 2018-12-31 | $508.85 Million | $104.65 Million | 0.206x | +164.91% |
| 2017-12-31 | $183.03 Million | $-57.99 Million | -0.317x | -5.54% |
| 2016-12-31 | $161.74 Million | $-48.56 Million | -0.300x | -189.10% |
| 2015-12-31 | $216.81 Million | $-22.52 Million | -0.104x | -124.67% |
| 2014-12-31 | $-5.70 Million | $-2.40 Million | 0.421x | -70.04% |
| 2013-12-31 | $-2.14 Million | $-3.01 Million | 1.406x | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more